Squarepoint Ops LLC Invests $241,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Squarepoint Ops LLC acquired a new stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 82,637 shares of the company’s stock, valued at approximately $241,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in shares of Poseida Therapeutics by 4.2% during the 2nd quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock worth $283,000 after acquiring an additional 3,875 shares in the last quarter. American Century Companies Inc. raised its holdings in Poseida Therapeutics by 5.9% during the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after purchasing an additional 5,023 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after purchasing an additional 9,672 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in Poseida Therapeutics during the first quarter worth $33,000. Finally, Marshall Wace LLP acquired a new stake in Poseida Therapeutics in the second quarter valued at $31,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Stock Performance

Poseida Therapeutics stock opened at $2.51 on Friday. Poseida Therapeutics, Inc. has a fifty-two week low of $1.83 and a fifty-two week high of $4.27. The company has a market capitalization of $243.80 million, a price-to-earnings ratio of -2.11 and a beta of 0.51. The stock has a fifty day moving average of $2.90 and a two-hundred day moving average of $2.90. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48.

Poseida Therapeutics (NASDAQ:PSTX) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. The business had revenue of $25.97 million for the quarter, compared to analysts’ expectations of $13.75 million. Poseida Therapeutics had a negative return on equity of 121.01% and a negative net margin of 127.48%. On average, analysts anticipate that Poseida Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Poseida Therapeutics in a research report on Tuesday, August 6th.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.